Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy Evaluation of CD19-CART Treatment for Refractory or Recurrent ALL

NCT03232619 is registered in ClinicalTrials.gov with Bioray Laboratories as lead sponsor.

NCT NCT03232619
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03232619 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy Evaluation of CD19-CART Treatment for Refractory or Recurrent ALL
Lead sponsor
Bioray Laboratories
Phase
Phase 1/2
Overall status
Completed
Start date
August 1, 2018
Completion date
September 15, 2020
Enrollment
4 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute leukemia